Consolidated Statements of Operations - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenues:
Total revenues	$ 9,153	$ 8,862	$ 26,364	$ 19,634
Operating expenses:
Cost of revenues	(4,416)	(4,199)	(12,232)	(7,882)
Research and development expenses	(4,032)	(3,221)	(11,637)	(10,239)
Selling, general and administrative expenses	(11,907)	(12,256)	(35,654)	(37,157)
Total operating expenses	(20,355)	(19,676)	(59,523)	(55,278)
Loss from operations	(11,202)	(10,814)	(33,159)	(35,644)
Other income (expense):
Other income, net	354	131	570	479
Interest expense, net	(146)	(221)	(559)	(678)
Loss before income taxes	(10,994)	(10,904)	(33,148)	(35,843)
Income tax benefit (expense)	(520)	252	(1,259)	(544)
Net loss	$ (11,514)	$ (10,652)	$ (34,407)	$ (36,387)
Loss per share
Basic loss ($ per share)	$ (4.21)	$ (5.27)	$ (13.55)	$ (23.17)
Diluted loss ($ per share)	$ (4.21)	$ (5.27)	$ (13.55)	$ (23.17)
Weighted average number of shares:
Basic (in shares)	2,732,749	2,021,070	2,539,408	1,570,389
Diluted (in shares)	2,732,749	2,021,070	2,539,408	1,570,389
Product revenue, net
Revenues:
Total revenues	$ 8,643	$ 7,858	$ 24,363	$ 14,928
Collaboration revenue
Revenues:
Total revenues	141	562	866	3,377
Research premium and grant revenue
Revenues:
Total revenues	$ 369	$ 442	$ 1,135	$ 1,329